<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01990443</url>
  </required_header>
  <id_info>
    <org_study_id>C38072/1107</org_study_id>
    <nct_id>NCT01990443</nct_id>
  </id_info>
  <brief_title>Absolute Bioavailability of Reslizumab in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open-Label, Parallel-Group, Single-Dose Study to Characterize the Absolute Bioavailability of Reslizumab (220 mg) Following Subcutaneous Administration to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the absolute bioavailability of reslizumab
      following administration of a single subcutaneous (sc) dose to healthy non-Japanese
      participants
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to assess the pharmacokinetics, safety and tolerability,
      immunogenicity, and pharmacodynamics of reslizumab
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute bioavailability</measure>
    <time_frame>From baseline to Day 140</time_frame>
    <description>Absolute bioavailability calculated as (AUC0-∞)sc/(AUC0-∞)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum drug concentration (Cmax)</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed serum drug concentration (tmax)</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time 0 to the time of the last measurable drug concentration (AUC0-t)</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage extrapolation</measure>
    <time_frame>From baseline to Day 140</time_frame>
    <description>Percentage extrapolation will be calculated as (AUC0-∞-AUC0-t)/(AUC0-∞)x100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent serum terminal elimination rate constant (λz)</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associated elimination half-life (t½)</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total serum clearance (CL)</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vz)</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Eosinophils Levels</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-reslizumab antibodies</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participants with Adverse Events</measure>
    <time_frame>From signing of consent form to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples for measurement of Anti-reslizumab antibodies</measure>
    <time_frame>Baseline, days 14, 28, 84, 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum drug concentration by time curve from time 0 to infinity (AUC0-∞)</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Absolute Bioavailability</condition>
  <arm_group>
    <arm_group_label>Reslizumab IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reslizumab 220-mg administered Intravenously (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reslizumab SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reslizumab 220-mg administered Subcutaneously (SC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reslizumab IV</intervention_name>
    <description>Reslizumab 220-mg intravenous (IV)</description>
    <arm_group_label>Reslizumab IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reslizumab SC</intervention_name>
    <description>Reslizumab 220 mg administered subcutaneous (SC)</description>
    <arm_group_label>Reslizumab SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria for Inclusion: Subjects may be included in the study if they meet all of the
        following criteria:

        All Subjects

          1. Written informed consent is obtained.

          2. The subject can read, speak, and write in English or Japanese (as applicable to the
             respective enrollment group).

          3. The subject is in good health as determined by medical and psychiatric history,
             physical examination, brief neurologic examination, ECG, serum chemistry, hematology,
             urinalysis, and serology.

          4. The subject, if a woman, is surgically sterile, 2 years postmenopausal, or, if of
             childbearing potential, is using a medically accepted method of contraception, and
             agrees to continued use of this method for the duration of the study and for 30 days
             after completion of the study. Acceptable methods of contraception include abstinence
             or an intrauterine device (known to have a failure rate of less than 1% per year).

          5. The subject must be willing and able to comply with study restrictions and to remain
             at the clinic for the required duration at each visit. Non-Japanese Subjects

          6. The subject has Caucasian parents and grandparents.

          7. The subject is a man or woman 18 through 45 years of age with a body mass index (BMI)
             of 20.0 to 30.0 kg/m2, inclusive (Appendix A). Note: At least half of the subjects
             enrolled into each treatment group must be within the more stringent age and weight
             criteria noted below for Japanese subjects.

             Also, every effort should be made to enroll an approximately equal number of men and
             women.

             Japanese Subjects

          8. The subject is a man or woman 20 through 45 years of age weighing 50 through 80 kg
             with a BMI of less than 28.0 kg/m2. Note: Every effort should be made to enroll an
             approximately equal number of men and women.

          9. The subject was born in Japan.

         10. The subject has Japanese parents and grandparents.

         11. The subject has lived less than 5 years outside Japan.

         12. The subject has a Japanese passport.

         13. The subject has no plans to leave the US until at least 1 week after the end of the
             study.

        Criteria for Exclusion: Subjects will be excluded from participating in this study if they
        meet 1 or more of the following criteria:

          1. The subject has any clinically significant uncontrolled medical conditions (treated or
             untreated).

          2. The subject has a clinically significant deviation from normal in ECG, physical
             examination, or brief neurologic examination findings, as determined by the
             investigator or the medical monitor.

          3. The subject is a pregnant or lactating woman. (Any women becoming pregnant during the
             study will be withdrawn from the study.)

          4. The subject has any disorder that may interfere with drug absorption, distribution,
             metabolism, or excretion (including gastrointestinal surgery; a history of
             appendectomy is allowed).

          5. The subject has received reslizumab in a previous study.

          6. The subject has received an immunosuppressant drug or anti-interleukin-5 (anti-IL-5)
             antibody within 6 months before the dose of study drug.

          7. The subject has received any investigational drug (non-biologic) within 30 days or 5
             half-lives (whichever is longer) before the dose of study drug, or in the case of a
             new chemical entity, 3 months or 5 half-lives (whichever is longer) before the dose of
             study drug.

          8. The subject has participated in any investigative biologics study within 6 months or 5
             half-lives (whichever is longer) before the dose of study drug.

          9. The subject has a known or suspected hypersensitivity or idiosyncratic reaction to
             anti-IL-5 antibodies, any compound present in the study drug, or monoclonal
             antibodies.

         10. The subject has a history of any clinically important drug, vaccine and/or other
             allergies or there is indication of potential for allergic reactions. Pharmacokinetic
             Study-Healthy Subjects Clinical Study Protocol Study C38072/1107 8

         11. The subject has received immunization with a live vaccine within 3 months prior to the
             dose of study drug or has immunization with a live or live attenuated vaccine planned
             within 3 months after the last dose of study drug.

         12. The subject had or was suspected of having a parasitic infestation/infection within 6
             months before the dose of study drug.

         13. The subject has used any vitamins within 2 weeks before the dose of study drug or has
             used any systemic or topical prescription, or nonprescription (over-the-counter [OTC])
             medication (except acetaminophen or ibuprofen) within 2 weeks or 5 half-lives
             (whichever is longer) before the dose of study drug.

         14. The subject has used any herbal or nutritional supplements within 2 weeks before the
             dose of study drug.

         15. The subject has donated blood or has a history of significant blood loss within 56
             days prior to the dose of study drug.

         16. The subject has donated plasma within 7 days prior to the dose of study drug.

         17. The subject has, after resting for 5 minutes, elevated blood pressure (defined as
             seated systolic blood pressure of more than 140 mm Hg and/or seated diastolic blood
             pressure of more than 90 mm Hg), or low blood pressure (defined as seated systolic
             blood pressure of less than 90 mm Hg and/or seated diastolic blood pressure of less
             than 45 mm Hg). (Only 2 rechecks of the subject's blood pressure are permitted for
             eligibility purposes.)

         18. The subject has, after resting for 5 minutes, a seated pulse of less than 45 or more
             than 90 beats per minute (bpm). (Only 2 rechecks of the subject's pulse are permitted
             for eligibility purposes.)

         19. The subject has, within the past 2 years, habitually consumed more than 21 units of
             alcohol per week, or has a history of alcohol, narcotic, or any other substance abuse
             as defined by the Diagnostic and Statistical Manual of Mental Disorders of the
             American Psychiatric Association, Fourth Edition, Text Revision (DSM-IV-TR) (American
             Psychiatric Association 2000). Note: For the purpose of this study, a unit of alcohol
             is equal to 1 ounce of hard liquor, 5 ounces of wine, or 8 ounces of beer.

         20. The subject has a positive urine drug screen (UDS) or alcohol test result.

         21. The subject has a clinical laboratory test value(s) outside the range(s) specified
             below, or any other clinically significant laboratory abnormality as determined by the
             investigator or medical monitor:

               -  hemoglobin value of less than 12 g/dL

               -  aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than 2
                  times the upper limit of the normal range (ULN)

               -  total bilirubin more than 25.7 μmol/L (1.5 mg/dL)

         22. The subject has a positive test result for human immunodeficiency virus (HIV),
             hepatitis B surface antigen (HBsAg) or antibodies to hepatitis C.

         23. The subject has, within 14 days before the dose of study drug, a clinically
             significant excessive consumption of coffee, tea, or other caffeine-containing
             beverages or food (ie, 600 mg/day of caffeine, 5 or more cups of coffee/day, or 10 or
             more cups of tea/day), or a combination of any of these beverages or foods.

         24. The subject is a user or former user of nicotine-containing products (including but
             not limited to cigarettes, cigars, and chewing or dipping tobacco) who stopped use or
             consumption (ie, smoking, chewing, or pinching) of these nicotine-containing products
             less than 12 months before study drug administration or is using or has used topical
             or oral nicotine preparations for smoking cessation within the past 3 months before
             study drug administration.

         25. The subject has had, within 4 weeks before the dose of study drug, a clinically
             significant illness, or within 1 week before the dose of study drug, any acute illness
             or, at screening or on the day before the first dose of study drug, has symptoms of
             any clinically significant or acute illness.

         26. The subject has significant active infection (acute or chronic) within 4 weeks before
             the dose of study drug. aa. The investigator feels that the subject should not be
             enrolled in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Teva Investigational Site 10567</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2013</study_first_submitted>
  <study_first_submitted_qc>November 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2013</study_first_posted>
  <last_update_submitted>March 27, 2014</last_update_submitted>
  <last_update_submitted_qc>March 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Reslizumab</keyword>
  <keyword>monoclonal antibody</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reslizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

